These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 32866560)

  • 1. Targeting and therapeutic peptide-based strategies for polycystic kidney disease.
    Wang J; Tripathy N; Chung EJ
    Adv Drug Deliv Rev; 2020; 161-162():176-189. PubMed ID: 32866560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vivo Imaging of Small Molecular Weight Peptides for Targeted Renal Drug Delivery: A Study in Normal and Polycystic Kidney Diseased Mice.
    Lenhard SC; McAlexander A; Virtue A; Fieles W; Skedzielewski T; Rambo M; Trinh H; Cheng SH; Hong H; Isidro-Llobet A; Nadin A; Geske R; Klein JL; Lee D; Jucker BM; Hu E
    J Pharmacol Exp Ther; 2019 Sep; 370(3):786-795. PubMed ID: 30936291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cellular pathways and potential therapeutics of Polycystic Kidney Disease.
    Richards T; Modarage K; Malik SA; Goggolidou P
    Biochem Soc Trans; 2021 Jun; 49(3):1171-1188. PubMed ID: 34156429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro 3D phenotypic drug screen identifies celastrol as an effective in vivo inhibitor of polycystic kidney disease.
    Booij TH; Leonhard WN; Bange H; Yan K; Fokkelman M; Plugge AJ; Veraar KAM; Dauwerse JG; van Westen GJP; van de Water B; Price LS; Peters DJM
    J Mol Cell Biol; 2020 Aug; 12(8):644-653. PubMed ID: 31065693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury.
    Aihara M; Fujiki H; Mizuguchi H; Hattori K; Ohmoto K; Ishikawa M; Nagano K; Yamamura Y
    J Pharmacol Exp Ther; 2014 May; 349(2):258-67. PubMed ID: 24570071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targets for polycystic kidney disease.
    Wilson PD
    Expert Opin Ther Targets; 2016; 20(1):35-45. PubMed ID: 26328773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic advances in the treatment of polycystic kidney disease.
    Riella C; Czarnecki PG; Steinman TI
    Nephron Clin Pract; 2014; 128(3-4):297-302. PubMed ID: 25573484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the pathogenesis and treatment of polycystic kidney disease.
    Patel V; Chowdhury R; Igarashi P
    Curr Opin Nephrol Hypertens; 2009 Mar; 18(2):99-106. PubMed ID: 19430332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug discovery for polycystic kidney disease.
    Sun Y; Zhou H; Yang BX
    Acta Pharmacol Sin; 2011 Jun; 32(6):805-16. PubMed ID: 21642949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in understanding the pathogenesis of polycystic kidney disease: therapeutic implications.
    Cowley BD
    Drugs; 2004; 64(12):1285-94. PubMed ID: 15200344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into targeting hepatic cystogenesis in autosomal dominant polycystic liver and kidney disease.
    Barten TRM; Bernts LHP; Drenth JPH; Gevers TJG
    Expert Opin Ther Targets; 2020 Jun; 24(6):589-599. PubMed ID: 32250187
    [No Abstract]   [Full Text] [Related]  

  • 12. Renal expression of a transforming growth factor-alpha transgene accelerates the progression of inherited, slowly progressive polycystic kidney disease in the mouse.
    Gattone VH; Kuenstler KA; Lindemann GW; Lu X; Cowley BD; Rankin CA; Calvet JP
    J Lab Clin Med; 1996 Feb; 127(2):214-22. PubMed ID: 8636651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mouse Pkd2 model gene expression reversion.
    Wilk EJ; Howton TC; Fisher JL; Oza VH; Brownlee RT; McPherson KC; Cleary HL; Yoder BK; George JF; Mrug M; Lasseigne BN
    Mol Med; 2023 May; 29(1):67. PubMed ID: 37217845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological Effects of Panduratin A on Renal Cyst Development in In Vitro and In Vivo Models of Polycystic Kidney Disease.
    Tonum K; Srimai N; Chabang N; Fongsupa S; Tuchinda P; Torres JA; Weimbs T; Soodvilai S
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats.
    Sabbatini M; Russo L; Cappellaio F; Troncone G; Bellevicine C; De Falco V; Buonocore P; Riccio E; Bisesti V; Federico S; Pisani A
    Am J Physiol Renal Physiol; 2014 May; 306(10):F1243-50. PubMed ID: 24647711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats.
    Wang X; Zhang S; Liu Y; Spichtig D; Kapoor S; Koepsell H; Mohebbi N; Segerer S; Serra AL; Rodriguez D; Devuyst O; Mei C; Wüthrich RP
    Kidney Int; 2013 Nov; 84(5):962-8. PubMed ID: 23715121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-Throughput Phenotypic Screening of Kinase Inhibitors to Identify Drug Targets for Polycystic Kidney Disease.
    Booij TH; Bange H; Leonhard WN; Yan K; Fokkelman M; Kunnen SJ; Dauwerse JG; Qin Y; van de Water B; van Westen GJP; Peters DJM; Price LS
    SLAS Discov; 2017 Sep; 22(8):974-984. PubMed ID: 28644734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
    Janssens P; Weydert C; De Rechter S; Wissing KM; Liebau MC; Mekahli D
    Pediatr Nephrol; 2018 Mar; 33(3):395-408. PubMed ID: 28455745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Potential Application of Chitosan Oligosaccharide for Attenuation of Renal Cyst Growth in the Treatment of Polycystic Kidney Disease.
    Pathomthongtaweechai N; Soodvilai S; Pichyangkura R; Muanprasat C
    Molecules; 2020 Nov; 25(23):. PubMed ID: 33261193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Activin Signaling Slows Progression of Polycystic Kidney Disease.
    Leonhard WN; Kunnen SJ; Plugge AJ; Pasternack A; Jianu SB; Veraar K; El Bouazzaoui F; Hoogaars WM; Ten Dijke P; Breuning MH; De Heer E; Ritvos O; Peters DJ
    J Am Soc Nephrol; 2016 Dec; 27(12):3589-3599. PubMed ID: 27020852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.